<DOC>
	<DOC>NCT01819948</DOC>
	<brief_summary>The purpose of this study is to determine whether the administration of the PhytoMed™ complement reduces CRP in women with histologically confirmed AJCC Stage 0-IIIA breast cancer which has been completely surgically resected and without evidence of disease as determined by their physician</brief_summary>
	<brief_title>Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women with histologically confirmed AJCC Stage 0IIIA breast cancer which has been completely surgically resected. No evidence of disease as determined by their physician. ER+ and/or PR+ tumour. Receiving an aromatase inhibitor (letrozole, anastrazole, exemestane) or tamoxifen at a stable dose for at least 3 months at trial entry. Postmenopausal women, defined as: (1) above 50 years of age who have not menstruated during the preceding 12 months or who have folliclestimulating hormone levels (FSH) &gt; 40 IU/L, (2) those under 50 years of age who have FSH hormone levels &gt;40 IU/L, or (3) those who have undergone a bilateral oophorectomy. CRP ≥3.9 mg/L measured as the mean of two consecutive weekly tests. Aged 18 years or older ECOG performance status 01 Between 2 and 5 years from their initial surgery for breast cancer. Life expectancy of at least 6 months At least 6 months since last chemotherapy Laboratory tests performed within 14 days of trial starting: 1. Granulocytes ≥ 1,500/µL; 2. Platelets ≥ 100,000/µL; 3. Haemoglobin ≥ 12.0 g/dL; 4. Total bilirubin equal to or below upper limit of normal (ULN); 5. AST and ALT equal to or below ULN; 6. Alkaline phosphatase equal to or below ULN; 7. Serum creatinine equal to or below ULN; Able to provide informed consent to receive the trial treatment, to provide biological specimens, selfadminister oral medication unsupervised for a prolonged period of time, and to complete a medication diary. Pregnancy or breastfeeding Who have had a malignancy (other than breast cancer) which required radiotherapy or systemic treatment within the past 5 years. Known cardiac disease (arrhythmias, myocardial infarction, bundle branch block, ischemic heart disease, uncontrolled hypertension) Known autoimmune disease or inflammatory disorder Any condition requiring the use of systemic corticosteroids or any other immunosuppressive agents (e.g. cyclosporin, tacrolimus, azathioprine). Women with known immunodeficiency (such as HIV). Patients with infection by septicaemia, infection, acute hepatitis, or other uncontrolled severe medical condition Routine use of aspirin &gt;81 mg/d or NSAIDs (&gt; 400 mg po 4 times/day of ibuprofen or naproxen &gt; 500 mg/d) or any use of celecoxib or similar COX2 inhibitors; Subjects are asked not to take dietary supplements, olives or olive oil for 1 month prior to trial enrolment and during the trial. Who are taking bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Stage 0-IIIA</keyword>
	<keyword>No evidence of disease</keyword>
</DOC>